Skip to main content

Bristol-Myers shares fall after it withdraws FDA application for combo lung cancer treatment

The New York-based pharmaceutical giant said it pulled its applications for a combination of its immunotherapy drugs Opdivo and Yervoy after recent discussions with the FDA.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.